GO
Loading...

Investors should expect more from Merck: Pro

Wednesday, 13 Aug 2014 | 11:40 AM ET

Raghuram Selvaraju, head of healthcare equity research at Aegis Capital, says "German Merck's" second quarter was "solid and respectable" but that its biopharmaceutical business is its weak spot.